孟鲁司特钠联合普米克令舒在小儿支气管哮喘急性发作中的疗效评估对炎症因子、免疫功能及气道高反应性的影响  

Effect of evaluate the efficacy of montelukast sodium combined with pramipexole in acute exacerbations of paediatric bronchial asthma on inflammatory factors,immune function and airway hyperresponsiveness

作　　者：李平真 李九英 刘丹华 LI Pingzhen;LI Jiuying;LIU Danhua(Kaifeng Children's Hospital,Endocrinology Department,Kaifeng 475000,China;Kaifeng Children's Hospital,Gastroenterology Department,Kaifeng 475000,China;Kaifeng Children's Hospital,Cardiovascular Department,Kaifeng 475000,China)

机构地区：[1]开封市儿童医院内分泌科,河南开封475000 [2]开封市儿童医院消化科,河南开封475000 [3]开封市儿童医院心血管科,河南开封475000

出　　处：《黑龙江医药科学》2025年第4期164-166,共3页Heilongjiang Medicine and Pharmacy

摘　　要：目的:探究孟鲁司特钠联合普米克令舒对小儿支气管哮喘急性发作中患儿的影响。方法:选取开封市儿童医院2022年4月至2024年4月收治的136例支气管哮喘急性发作患儿展开研究,按入院时间分为对照组与研究组。对照组采用常规治疗,研究组采用孟鲁司特钠联合普米克令舒治疗。比较两组临床疗效、炎症因子、免疫功能及气道高反应性的差异。结果:研究组治疗效率高达94.12%,相较于对照组82.35%差异有统计学意义(P<0.05)。治疗后患儿肿瘤坏死因子a(tumor necrosis factor-alpha, TNF-a),白介素6(interleukin-6,IL-6)、高敏C反应蛋白(hypersensitive-c-reactive-protein, hs-CRP)、CD4~+T淋巴细胞(CD4~+ T lymphocyte count, CD4~+)、CD8~+T淋巴细胞(CD8~+ T lymphocyte, CD8~+)、免疫球蛋白A(immunoglobulin A,IgA)、免疫球蛋白M(immunoglobulin M,IgM)指数均更优,研究组优于对照组,差异有统计学意义(P<0.05)。研究组PC35sGaw浓度优于对照组(P<0.05)。结论:孟鲁司特钠联合普米克令舒通过降低炎症因子水平、气道高反应性,调节免疫功能,可有效缓解哮喘症状。Objective:A study to investigate the effect of montelukast sodium combined with pramipexole on children in acute exacerbation of paediatric bronchial asthma.Methods:A total of 136 children with acute exacerbation of bronchial asthma in Kaifeng Children's Hospital from April 2022 to April 2024 were selected for the study,and they were divided into the control group and the study group according to the time of admission.The control group was treated with conventional treatment,and the study group was treated with montelukast sodium combined with pramipexole.The differences in clinical efficacy,inflammatory factors,immune function and airway hyperresponsiveness between the two groups were compared.Results:The treatment efficiency of the study group was 94.12%,which demonstrated a significant advantage over the control group of 82.35%(P<0.05).Count(CD4+T Lymphocyte,CD4+),CD8+T Lymphocyte(CD8+),immunoglobulin A(IgA),and immunoglobulin M(IgM)indices were better in the study group than in the control group,with statistically significant differences.control group,and the difference was statistically significant(P<0.05).PC35sGaw concentration was better in the study group than in the control group(P<0.05).Conclusion:Montelukast sodium combined with pramipexole can effectively relieve asthma symptoms by reducing the level of inflammatory factors,airway hyperresponsiveness,and regulating immune function.

关 键 词：孟鲁司特钠 普米克令舒 小儿支气管哮喘 炎症因子 免疫功能 气道高反应性 

分 类 号：R725.6[医药卫生—儿科]